2 news items
Travere Therapeutics Reports First Quarter 2024 Financial Results
TVTX
6 May 24
measures enhances the ability of investors to compare its results from period to period and allows for greater transparency with respect to key financial
Reported Earlier, Travere Therapeutics And CCL Vifor Get European Commission Approval Of Sparsentan For The Treatment Of IgA Nephropathy.
TVTX
19 Apr 24
https://ec.europa.eu/transparency/documents
- Prev
- 1
- Next